References
- Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6) , 2403–2413 (1997).
- Cunningham D , ChauI, StockenDD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27(33) , 5513–5518 (2009).
- Conroy T , DesseigneF, YchouM et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19) , 1817–1825 (2011).
- Moore MJ , GoldsteinD, HammJ et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15) , 1960–1966 (2007).
- Starling N , WatkinsD, CunninghamD et al. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J. Clin. Oncol. 27(33) , 5499–5505 (2009).
- Von Hoff DD , RamanathanRK, BoradMJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J. Clin. Oncol. 29(34) , 4548–4554 (2011).
- Ueno H , KiyosawaK, KaniwaN. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer.97(2) , 145–151 (2007).
- Heinemann V , XuYZ, ChubbS et al. Cellular elimination of 2´,2´-difluorodeoxycytidine 5´-triphosphate: a mechanism of self-potentiation. Cancer Res. 52(3) , 533–539 (1992).
- Regine WF , WinterKA, AbramsR et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 Phase III trial. Ann. Surg. Oncol. 18(5) , 1319–1326 (2011).
- Farrell JJ , ElsalehH, GarciaM et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1) , 187–195 (2009).
- Shi JY , ShiZZ, ZhangSJ et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14(11) , 759–768 (2004).
- Sebastiani V , RicciF, Rubio-ViqueiraB et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin. Cancer Res. 12(8) , 2492–2497 (2006).
- Gilbert JA , SalavaggioneOE, JiY et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6) , 1794–1803 (2006).
- Li D , FrazierM, EvansDB et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J. Clin. Oncol. 24(11) , 1720–1728 (2006).